Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

• Main Authors: April W. Armstrong (Author), Sang Hee Park (Author), Vardhaman Patel (Author), Pierre Nicolas (Author), Wei-Jhih Wang (Author), Matthew J. Colombo (Author), Viktor Chirikov (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determine the overall 52-week cumulative clinical benefit of treatment initia...